Zotiraciclib

N/A

Report date: 2026/02/24 20:00:16
NME

Base Information

Drug NameZotiraciclib
Drug Alias NameSB-1317TG-02
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCyclin-dependent kinase 9 inhibitorsTyrosine-protein kinase JAK2 inhibitorsCyclin-dependent kinase 7 inhibitors +[6] 
TargetsCyclin-dependent kinase 1Tyrosine-protein kinase JAK2Tyrosine-protein kinase receptor FLT3 +[6] 
Therapy Area/IndicationsBrain NeoplasmsCarcinoma, HepatocellularGliosarcoma +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNetherlandsAustria +[7] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSyncore Biotechnology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesNational Cancer InstituteEuropean Organisation For Research And Treatment Of CancerCothera Bioscience Hong Kong Ltd +[4] 
Inactive CompaniesLee'S Pharmaceutical LtdTragara Pharmaceuticals Inc
Active IndicationsBrain NeoplasmsGlioblastomaAstrocytoma +[4] 
Inactive IndicationsCarcinoma, HepatocellularGliosarcomaLeukemia, Lymphocytic, Chronic, B-Cell +[4] 

Other Information

ATC CodeN/A
Related LinksN/A